Skip to Main Content

Good morning, everyone, and welcome to the middle of the week. You made it this far, so why not carry on? Our survival plan calls for quaffing a cup or three of delicious stimulation — peppermint mocha is on our menu. As always, you are welcome to join us. Remember — no prescription is required. So time to get cracking. After all, meetings, phone calls, and deadlines are looming. To help you along, we have gathered the usual menu of tidbits. We hope you find them helpful. Meanwhile, have a wonderful day and do stay in touch …

A U.S. appeals court upheld a ruling that a crucial patent on Johnson & Johnson’s (JNJ) blockbuster Remicade arthritis treatment is invalid, because the concepts were covered in a prior J&J patent. The decision limits J&J’s ability to seek damages from Pfizer (PFE), which already launched a lower-cost biosimilar version of the drug, but recently filed a lawsuit claiming J&J illegally maneuvered insurers to stifle sales of its Inflectra medication.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!